Nayel Sayegh
Urology · Yonkers, NYNPI 1750486031
Payments from drug & device makers
Across 240 payments — averaging $38.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$4K
- Johnson & Johnson$1K
- Astellas Pharma US Inc$1K
- Urovant Sciences Inc$619
- Endo Pharmaceuticals Inc.$357
- AbbVie$352
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,47348%
- Education$1,02311%
- Other$3,77141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 1 | $3,771 |
| Johnson & Johnson(2 entities) | 65 | $1,251 |
| Astellas Pharma US Inc | 36 | $1,013 |
| Urovant Sciences Inc | 22 | $619 |
| Endo Pharmaceuticals Inc. | 13 | $357 |
| AbbVie(2 entities) | 17 | $352 |
| Myovant Sciences Inc. | 14 | $335 |
| Novo Nordisk | 2 | $243 |
| Pfizer | 11 | $200 |
| Coloplast | 12 | $167 |
| Antares Pharma, Inc. | 6 | $128 |
| Clarus Therapeutics Inc. | 6 | $124 |
| Merck | 6 | $109 |
| Acerus Pharmaceuticals Corporation | 6 | $104 |
| Alnylam Pharmaceuticals Inc. | 3 | $81 |
| Bayer | 4 | $81 |
| Sumitomo Pharma America, Inc. | 2 | $52 |
| Teleflex LLC | 2 | $44 |
| GSK | 2 | $43 |
| Aytu Biopharma, Inc. | 2 | $41 |
| Dentsply IH Inc. | 2 | $36 |
| Foundation Medicine, Inc. | 1 | $28 |
| Blue Earth Diagnostics | 1 | $23 |
| Therapeuticsmd, Inc. | 1 | $21 |
| Axonics, Inc. | 1 | $19 |
| Photocure Inc | 1 | $15 |
| Rochester Medical Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CYSTO-NEPHRO VIDEOSCOPE$3,771
- GEMTESA$250
- Ozempic$243
How this compares
$9,267 in reported general payments places this provider in the 75th percentile of 952 urology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 14 | $9,078 |
| Tamsulosin Hcl | 33 | $450 |
| Finasteride | 21 | $287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,013 | $9,07814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 urology providers in New York.
Other urology in Yonkers
- Christopher PieczonkaSyracuse$31.2M
- Guarionex DecastroNew York$5.7M
- Mitchell EfrosGarden City$4.2M
- James McKiernanNew York$4.1M
- William HuangNew York$3.9M
- Jed KaminetskyMiddle Village$3.5M
- Evan GoldfischerPoughkeepsie$3.1M
- Gennady BratslavskySyracuse$2.5M
- Ashutosh TewariNew York$2.5M
- Manish ViraNew Hyde Park$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.